Dianthus jumps after nerve disease drug shows faster‑than‑expected response in trial

Dianthus Therapeutics

09/03/2026 16:53

** Shares of Dianthus Therapeutics DNTH.O rise 26% to over four-year high of $82.27

** Co says it reached an early "go" decision on its experimental drug for a rare nerve disease ahead of schedule in a late‑stage trial

** A "go" decision means the trial has shown enough early success for the company to move forward to the next stage of the trial

** DNTH is testing the drug, claseprubart, in patients with chronic inflammatory demyelinating polyneuropathy, a rare autoimmune disease where the body attacks the protective coating around nerves, causing weakness, numbness, and loss of balance

** The company hit its goal early after 20 patients responded to the drug before all 40 had completed the first part of the trial

** The "decision comes ahead-of-schedule and beats our expectations," says Cantor analysts', calling it a "clinical de-risking event" that supports a potential drug approval filing

** In 2025, DNTH rose 77.6%

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))